Moderna Inc. (NASDAQ: MRNA) reported total revenue of $5.1 billion for the fourth quarter of 2022, down 29% year-over-year due to a drop in COVID-19 vaccine sales.
Net income decreased by 70% to $1.5 billion while EPS dropped by 68% to $3.61 compared to the same period last year.
The company expects product sales of approx. $2 billion in the first half of 2023.
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Delta Air Lines (DAL) Q2 2025 Earnings: Key financials and quarterly highlights
Delta Air Lines (NYSE: DAL) reported its second quarter 2025 earnings results today. Operating revenue remained flat versus the year-ago quarter at $16.64 billion. GAAP net income increased 63% year-over-year
PepsiCo likely to report weak Q2 results as North America demand slumps
After entering fiscal 2025 on a low note, PepsiCo, Inc. (NASDAQ: PEP) is gearing up to publish its second-quarter results. The company is facing sales pressure amid geopolitical tensions and
Bank earnings preview: These banking leaders will report Q2 2025 results next week, what to expect
The earnings season is set to kick off next week with quarterly reports from a number of leading banks. JPMorgan Chase & Co. (NYSE: JPM), Citigroup (NYSE: C) and Wells
